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Translation of mRNA is a highly regulated process that is tightly coordinated
with cotranslational protein maturation. Recently, mRNA modifications and
tRNA modifications – the so called epitranscriptome – have added a new
layer of regulation that is still poorly understood. Both types of modifications
can affect codon–anticodon interactions, thereby affecting mRNA translation
and protein synthesis in similar ways. Here, we describe an updated view on
how the different types of modifications can be mapped, how they affect
translation, how they trigger phenotypes and discuss how the combined action
of mRNA and tRNA modifications coordinate translation in health and
disease.
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Protein synthesis is essential to life. Thus, it is regu-
lated by a variety of sophisticated mechanisms and
comprises four phases: (a) initiation; (b) elongation; (c)
termination; and (d) ribosome recycling. Initiation is
the key regulatory step of translation, and different
mechanisms have been discovered that lead either to a
global or transcript-specific control of translation initi-
ation [1]. However, translation initiation is not the
only option for the cell to regulate protein synthesis.
Translation elongation comprises mRNA decoding,
peptide-bond formation and tRNA–mRNA transloca-
tion, resulting in nascent-peptide elongation, and each
of these steps bears regulatory potential for transla-
tion. Furthermore, mRNA translation occurs in
concert with protein maturation. As soon as the nas-
cent-peptide chain emerges from the ribosome during
protein synthesis, proteins begin to fold into their final
three-dimensional structure and acquire protein modi-
fications [2].
Some of the key players in translation like mRNA,
tRNA or ribosomes are RNA molecules or contain
RNA molecules, essential to their function. These can
be post-transcriptionally modified by a plethora of
chemical modifications, which currently amount to
more than a hundred seventy [3–5]. Some of these
RNA modifications are evolutionary conserved and
were linked to a human disease [6–8]. Since RNA
modifications change the structural and chemical prop-
erties of RNA molecules, some modifications of either
mRNA, tRNA or rRNA are thought to optimize
translation dynamics in the cell, whereas others may
be neutral to translation [5]. In particular internal
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mRNA modifications and tRNA anticodon modifica-
tions likely lead to very similar effects, since the codon
and the anticodon interact directly during decoding.
Importantly, the reversibility of both types of modifi-
cations suggests a new, essentially unexplored layer of
the control of gene expression that has been termed
the epitranscriptome [9,10]. However, how particular
mRNA or tRNA modifications affect translation is
largely unknown because the analysis of eukaryotic
translation in vitro or in vivo and the identification of
internal mRNA modifications is very challenging.
Here, we discuss our emerging understanding of the
role of mRNA modifications [N6-methyladenosine
(m6A), 5-methylcytosine (m5C), N4-acetylcytidine
(ac4C), 20-O-methylation] and tRNA wobble uridine
(U34) modifications in translation and how our under-
standing of the roles of mRNA modifications is influ-
enced by current mapping approaches. Finally, we
comment on general implications for disease. This arti-
cle aims to convey a broad picture of how mRNA and
tRNA modifications act in concert to control transla-
tion. For a more focused discussion of mRNA and
tRNA modifications we refer the readers to several
recent reviews [9,11–20].
Internal mRNA modifications and their
mapping
Internal modifications of mRNA and long noncoding
RNA have already been discovered in the 1970s [21–23].
However, due to their low abundance they generally
evaded biochemical analyses and we lacked the ability
to map their positions in a transcriptome-wide manner.
mRNA modification mapping has become possible only
recently, with the advent of deep sequencing and the
implementation of specialized sequencing-based proto-
cols. In general, successful mapping approaches are
based on three strategies: (a) the induction or detection
of specific mutations in RNAseq experiments; (b) termi-
nation of reverse-transcription (RT) reactions and (c)
antibody-based enrichment of modification sites (exten-
sively reviewed in [18]). Direct RNA sequencing appears
as a promising future alternative and has been shown to
detect modified bases in synthetic RNA strands or
abundant cellular targets [24]. However, these protocols
have not been shown to work reliably on a transcrip-
tome-wide level, yet. It is important to realize that the
low abundance of mRNA modifications in combination
with false-positive rates in their detection has remained
a challenge. Due to the lack of quantitative high-quality
mRNA modification maps for most organisms we can-
not easily correlate translational phenotypes to the
occurrence of mRNA modifications. This has prevented
us from understanding the in vivo roles of mRNA modi-
fications and in particular from understanding their
effects during translation.
The most abundant internal mRNA modification is
m6A, which is present on average at 3 positions per
mRNA molecule (Box 1). In addition to m6A, pseu-
douridine (Ψ), N1-methyladenosine (m1A), N6,20-O-
dimethyladenosine (m6Am), as well as m5C (Box 2) and
its oxidation product 5-hydroxymethylcytosine (hm5C),
ac4C and 20-O-methylated nucleotides were mapped to
the transcriptome. Additional modifications were
reported based on measurements by RNA mass spec-
trometry but their position has not been determined
throughout the transcriptome [9,25]. The complex modi-
fication pattern of the transcriptome likely differs
between species and even between different tissues in
one organism [26]. However, a complete map of all
modifications in all cell types, still needs to be achieved
and will require concerted efforts from many labs com-
parable to consortia like the ENCODE project [27].
Internal mRNA modifications in
translational regulation
The recent identification of proteins that install (writ-
ers), recognize (readers) and remove (erasers) m6A and
other modifications has revealed mechanisms how
mRNA modifications can affect nearly every aspect of
the mRNA life cycle, as well as various cellular, devel-
opmental and disease processes. However, for under-
standing their effects in translation, we currently have
to mostly rely on biochemical and biophysical analy-
ses. Using an in vitro protein synthesis kit containing
the components for in vitro transcription and transla-
tion, named ‘PUR-Express translation system’ with
m5C, m6A, Ψ or 20-O-methylated nucleotides at each
position within a codon revealed that protein synthesis
is strongly affected by nucleotide modifications in a
position-specific manner [28]. 20-O-methylated nucleo-
tides at the 1st codon position affect translation only
marginally; however, when placed at the 2nd position
the same modification causes an almost complete stop
of protein synthesis. Introduction of multiple modified
nucleotides within one codon increased the translation
inhibition [28]. More specifically, the presence of 20-O-
methylation at the 2nd codon position of mRNA
strongly delays tRNA accommodation to the modified
codon [29]. Furthermore, 20-O-methylation impairs the
initial and proofreading selection of aminoacyl-tRNA
and the interaction between the codon–anticodon helix
and ribosomal-monitoring bases [29]. Such alterations
of codon–anticodon interaction can even change the
identity of the incorporated amino acid as the presence
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of m5C at the 2nd codon position of CCC – a proline
codon – leads to an amino acid-substitution by either
isoleucine or leucine [28].
A FRET-based assay using a bacterial translation
system revealed that m6A at the 1st codon position
strongly inhibits translation elongation dynamics [30].
m6A acts as a barrier to tRNA accommodation when
present at the 2nd codon position. However, when pre-
sent at the 3rd codon position of the near-cognate
codon m6A essentially does not affect tRNA selection
rate during translation elongation [30]. In addition, to
the position of the modification, the sequence context
also has a significant modulatory effect [28,30]. For
instance m6A in the glutamine (CAG) or proline
(CCA) slowed translation elongation and Ψ at the 1st
position of the UAA stop codon increases transla-
tional read-through [30,31]. However, translation elon-
gation is not the only step that can be affected by
nucleotide modifications. m6A like the cap, when pre-
sent in the 50 UTR of mRNAs can modulate transla-
tion initiation. Even a single m6A nucleotide in the 50
UTR induces direct binding of mRNA to eukaryotic
initiation factor 3 (eIF3), and is sufficient to recruit
the 43S complex to initiate translation in the absence
of the cap-binding initiation factor, eIF4E [32]. Fol-
lowing heat shock, m6A was found more frequently in
Hsp70 mRNA regulating its cap-independent transla-
tion [32], an effect that appears to be mediated by
ABCF1, a key factor in m6A-promoted translation
under both physiological and stress conditions [33].
Transcriptome-wide mapping of the ac4C, catalysed
by acetyltransferase NAT 10, revealed ac4C enrich-
ment within coding regions of mRNA [34]. Further-
more, mRNA stability was decreased in NAT10-
Box 1: Mapping of m6A sites
The mapping of m6A sites is the classical example for detection based on modification-specific antibodies [80,81]. Early
protocols randomly fragment the mRNA and enrich m6A-containing mRNA fragments by immunoprecipitation (IP)
using m6A-specific antibodies. The purified mRNA pool and a negative control are subsequently converted to cDNA
and sequenced. Putative m6A sites are identified as m6A peaks that are absent in the control. While this strategy is
sufficient to identify the position of m6A sites at a global level, it does not reach nucleotide resolution. Nucleotide
resolution was later achieved by UV cross-linking the antibodies to mRNA prior to the IP called individual-nucleotide-
resolution cross-linking and IP (miCLIP) [19,82,83]. The cross-link between RNA and the antibody leads to
characteristic nucleotide substitutions that can be detected in the sequencing reaction. Antibody-based purification
strategies have also been used for m1A, m6Am, hm5C and ac4C [18,19]. While m1A interferes with Watson–Crick
basepairing, m6A is not distinguished from adenosine by standard RT enzymes. However, different strategies can be used
to increase the mutation rates in such experiments like varying the concentration of dNTPs, using modified polymerases
that are sensitive towards specific modifications or using selenium-modified deoxythymidine triphosphate analogues [84–
86]. An orthogonal strategy is to use analogues of S-adenosyl-L-methionine (SAM) [87]. Since SAM analogues are
unstable under physiological conditions, cells are fed with propargyl-L-selenohomocysteine, which is converted to the
respective SAM analogue by the cellular methionine adenosyltransferase [87]. Subsequently, cellular methyltransferases,
which are often promiscuous towards their substrate use the SAM analogue and incorporate the methyl derivate into
mRNA. The artificial label can then be used to enrich the labelled mRNA by chemical click reactions and to induce
mutations and/or strand termination in the RT reaction [87].
Box 2: Mapping of m5C sites
m5Cwas the firstmodified nucleotide, whichwasmapped
to the entire transcriptome after adapting bisulfite-
conversion sequencing to RNA [17]. The method takes
advantage of the fact that methylation changes the
chemical reactivity of cytidine. While acidic bisulfite
deamination converts cytidine to uridine, m5C is resistant
to this conversion reaction. Therefore, the detection of
m5C relies on the identification of cytidines that do not
convert in response to bisulfite treatment. In identifying
thousands of m5C sites throughout the transcriptome
RNA-bisulphite sequencing has become the first example
for identifying internal mRNA modifications in high
throughput. However, the high number of m5C sites has
been questioned, showing how much care needs to be
taken not tomisinterpretmodificationmarks thatmay be
the result of single-nucleotide polymorphisms, inefficient
chemical reactions or sequencing errors [20,88].
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deleted HeLa cells indicating that ac4C actively pro-
motes mRNA stability and enhances translation. ac4C
is strongly enriched in the 50 end of mRNA, however,
no effect of ac4C on the formation of 48S preinitiation
complex was observed by in vitro analysis, demonstrat-
ing that ac4C does not affect translation initiation [34].
Finally, ribosome-profiling data show increased ribo-
some occupancy for acetylated mRNA mediated by
NAT10, suggesting that ac4C intrinsically promotes
translation, a finding further supported in vivo by the
quantification of translation products from parental
and NAT10-depleted cells [34].
Taken together, the emerging data suggest a direct
impact of internal mRNA modifications on gene
expression, primarily through translation.
tRNA modifications and their mapping
tRNAs contain the largest diversity of modified
nucleotides [12,35]. Eukaryotic tRNAs contain on
average 13 modifications, including various methyla-
tions, pseudouridine, dihydrouridine, thiolation and
others. Modifications are found throughout the tRNA
molecule, with a hotspot in the anticodon loop. The
modifications in the anticodon loop fine-tune decod-
ing, translational fidelity and translational efficiency,
whereas tRNA modifications outside the anticodon
loop mainly affect tRNA stability and modulate tRNA
folding [12]. Furthermore, both classes of modifica-
tions act as determinants for aminoacyl-tRNA syn-
thetase binding to tRNA. In recent years, numerous
independent studies established an unexpected role of
tRNA modifications and the enzymes catalysing such
modifications for the aetiology of complex human
pathologies including cancer, neurological and respira-
tory disorders and mitochondrial diseases [6–8,36].
Compared to mRNA, tRNA are very abundant.
Hence, their modifications have been characterized
using RNA mass spectrometry and biochemical meth-
ods, whereas similar methods were challenging for
mRNA [37]. Nevertheless, the simultaneous quantifica-
tion of tRNA and their modifications in high through-
put remains challenging, since sequence-specific RNA
mass spectrometry is not commonly used and some
RNA modifications perturb sequencing-based detec-
tion. However, recent tRNA-sequencing protocols like
ARM-Seq have improved the situation [38,39].
Wobble uridine in translational
processivity
The ability of cells to respond and to adapt to dynami-
cally changing external conditions and stimuli are
ensured by the coordinated processes of transcription,
translation and maintenance of protein homeostasis.
During this process, tRNA modifications appear criti-
cal for maintaining this coordination [40–42]. In all
known organisms wobble U34 carries a complex modi-
fication at its 50 position and a 2-thio-group (s2U) in
tRNALys(UUU), tRNAGln(UUG) and tRNAGlu(UUC).
These tRNA decode A-ending codons of split codon
boxes where U- and C-ending codons code for a dif-
ferent amino acid. Furthermore, U34 modifications
were shown to be a determinant of efficient aminoacy-
lation of tRNAGlu and tRNAGln by increasing the
binding affinity of the synthetase in Escherichia coli
but not in yeast [43–45]. On the ribosome, tRNA wob-
ble modifications are implicated in maintaining accu-
rate decoding and translational processivity. In
bacteria, cmo5U34 in tRNAAla(UGC) facilitates the
decoding of codons ending with A, G and U, accord-
ing to the wobble rules, but also the C-ending codon
with reduced efficiency [46]. In tRNAGln(UUG) s2U34
affects the hydrolysis of GTP by EF-Tu and subse-
quently dipeptide formation [47]. Since the ratio
between the rates of GTP hydrolysis and peptide bond
formation is similar for s2U modified and unmodified
tRNAGln(UUG), it is likely that the modification prefer-
entially affects GTP hydrolysis and inorganic phosphate
(Pi) release with little effect on later steps in decoding
[47]. In eukaryotes, tRNALys(UUU), tRNAGln(UUG) and
tRNAGlu(UUC) are decorated by 5-methoxycarbonyl-
methyl-2-thiouridine (mcm5s2U34). The absence of
either of the two modifications leads to a codon-specific
slowdown of translation of the AAA and CAA codons,
which are decoded by tRNALys(UUU), tRNAGln(UUG)
[40,48]. GAA is not decoded more slowly in the yeast
mutant, consistent with the observation that reading-
frame maintenance of these codons depends on the
mcm5s2U modifications only for tRNALys(UUU) and
tRNAGln(UUG) [49] and that the overexpression of
tRNAGlu(UUC) is not able to rescue growth phenotypes
[50,51]. Hence, the absence of the modifications affects
the global translation of a subset of mRNAs enriched
for codons that are read by these tRNAs [52]. A com-
parison of the decoding properties of native modified
and unmodified tRNAs in an in vitro translation system
showed that U34 modifications increase the affinity of
the tRNA to its cognate codon in the A site of the ribo-
some [46,52]. Also the rate of peptide-bond formation
at saturating concentrations of the ternary complex is
slower in the absence of s2U34 or mcm5U34 [52]. A
real-time kinetic analysis shows that hypomodified
tRNALys(UUU) that only carries mcm5U34 but lacks
s2U34 binds to its cognate codon with a lower affinity
and is more frequently rejected than the fully modified
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tRNALys(UUU). Nevertheless, the rate of peptide-bond
formation remains unaffected [53]. Altogether, these
data demonstrate a role of tRNA wobble uridine modi-
fications at the initial steps of decoding and also during
the proofreading step [53].
But how are the observed translational defects linked
to phenotypes and to the regulation of gene expres-
sion? Several studies have shown that 2-thiolation of
tRNALys(UUU), tRNAGln(UUG) and tRNAGlu(UUC) is
decreased at elevated temperature in yeast [54–57] and
that this effect is reversible when normal growth condi-
tions are restored [56,57]. A study utilizing quantitative
mass spectrometry and northern-blot analyses showed
a decrease in s2U34 under permissive growth condi-
tions upon nutrient starvation. However, thiolation
pattern remained unaffected when sufficient nutrients
were supplied at elevated growth temperature, thereby
establishing that the reduction in 2-thiolation under
heat stress is independent of nutrient availability [54].
Under most circumstances, the lack of tRNA modifica-
tions induces cellular stress and negatively affects cell
growth and survival [58]. Nevertheless, the absence of
tRNA modifications can also be beneficial in specific
cases, for example by conferring resistance to endoplas-
mic reticulum stress [55] or resistance to long-term
nutrient starvation [59]. This indicates that the link
between wobble uridine modifications and stress is
more complex than it seems.
Hypomodification and protein
homeostasis
Modifications of tRNA optimize translation dynamics,
which is crucial to maintain cellular homeostasis [40,60].
Several studies have characterized mutants that are defi-
cient in wobble uridine modification using RNAseq,
ribosome profiling and quantitative proteomics
[40,48,52,54]. While no major translation defect was
apparent based on S35 incorporation and polysome pro-
filing [40,52], gene ontology analysis of downregulated
genes and proteins linked the loss of U34 modifications
to processes like rRNA synthesis and processing, ribo-
some biogenesis, tRNA synthesis and modification, elec-
tron transport chain and oxidative phosphorylation,
and translation regulation, which are typically downreg-
ulated during the response to numerous stresses
[40,52,54,61,62]. Analyses of codon translation by ribo-
some profiling in yeast cells lacking wobble uridine
modifications revealed a seemingly mild enrichment of
~ 20% of AAA and CAA codons in the A site of
mutant ribosomes relative to wild-type [40,48,63]. This
is in agreement with a slight enrichment of AAA, CAA
and GAA codons in mRNAs that appear reduced at the
proteomic level [52] and an in vitro study that showed
that the absence of s2U34 affects the stability of
tRNALys(UUU) binding to the ribosome during decod-
ing and impedes rotation of ribosomal subunits upon
Fig. 1. Cellular outcomes of the presence
or absence of tRNA anticodon
modifications. Fully modified tRNAs
ensure optimal translation through optimal
decoding and translocation (left panel)
resulting in a properly folded proteome.
Slow decoding and translocation occurs
due to loss of tRNA anticodon
modifications (right panel), resulting in
higher ribosome occupancy – indicative of
a translation slowdown – at the codons
requiring modified tRNAs and protein
homeostasis defects.
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tRNA–mRNA translocation [53]. The lack of s2U34
modification increases the length of the decoding steps
and slows down translocation such that the residence
time of the ribosomes on Lys-codon AAA increased
by 20–40%, clearly accounting for the modest increase
in the ribosome occupancy revealed by ribosome pro-
filing [40,48,53]. Strikingly, however, the subtle trans-
lation defects are accompanied by a perturbation of in
cellular protein homeostasis leading to the upregula-
tion of cytoplasmic chaperones and the proteasome
and lead to the formation of protein aggregates in the
mutants [40] (Fig. 1). Similar phenotypes were
observed in different modification mutants and may
point to a common mechanism how defects in tRNA
modifications induce phenotypes [41,64]. Interestingly,
protein aggregates isolated from such cells are similar
to those induced by the loss of ribosome-associated
chaperones, responsible for cotranslational folding of
nascent polypeptides and preventing them from incor-
rect folding [40,65]. Finally, the protein aggregates in
wobble uridine modification mutants are not enriched
for AAA, CAA and GAA codons, but contain mainly
proteins that are known to be metastable [40,65].
Taken together, the absence of tRNA modifications
induces seemingly mild effects on translation dynam-
ics. However, those perturbations can significantly
impact on cellular viability through its profound nega-
tive effect on protein homeostasis.
The epitranscriptome: implication in
disease
Mutations in nearly half of the RNA modification
enzymes have been linked to human diseases, including
Fig. 2. tRNA modifications associated with human diseases. Schematic representation of a cytoplasmic tRNA with disease-linked
modifications and the name of the associated diseases.
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cancer, neurological disorders, genetic birth defects,
cardiovascular diseases, mitochondrial-linked defects
and metabolic disorders [8] (Fig. 2). Interestingly,
amongst the diseases that have been associated with
mutations in RNA modifying enzymes, neurological
disorders are the most prevalent. This is in agreement
with the observed enrichment of various RNA modifi-
cations in neuronal tissues [66,67]. The m5C methyl-
transferase NSUN2 has been associated with defects in
memory and learning in Drosophila [68]. Furthermore,
tRNA fragments were shown in NSUN2-deficient
mice, which may activate apoptosis in the brain [69].
RNA demethylation has also been linked to neurologi-
cal defects. The deletion of the RNA demethylase
FTO in mice results in an impairment of dopamine
receptor control of neuronal activity and behaviorial
responses [70]. ALKBH5, a second m6A demethylase
has been associated to major depressive disorders [71].
In addition, mutations that affect 5-taurinomethy-
luridine (sm5U) biosynthesis in mitochondrial tRNAs
are associated with mitochondrial diseases and affect
the translation of lysine and leucine codons. MTO1
and GTPBP3 catalyse the formation sm5U and
GTPBP3-knockout exhibit respiratory defects and
reduced mitochondrial translation, however, little is
known about the mechanism [72–74].
Defects in tRNA modifications and mRNA modifi-
cations have also been directly tied to cell proliferation
and malignancy in a number of lymphomas, leukae-
mias and carcinomas, including breast, bladder and
colorectal cancers [6,75–77]. Elp3 and Ctu1/2, enzymes
responsible for mcm5s2 modification are upregulated in
breast cancer and were shown to be required to sustain
metastasis [78]. NSUN2 is a direct target gene of c-
Myc, a well-known proto-oncogene and has been
found to be upregulated in primary tumours and
metastases of breast carcinomas [79]. The reduction in
m6A levels through knockdown of Mettl3 results in
tumour progression [77]. Taken together, these point to
a crucial role of RNA modifications in human diseases.
Concluding remarks
This review aims to summarize the emerging view of
internal mRNA and tRNA modifications – the so
called epitranscriptome – as regulators of translation
and protein homeostasis. In the last decade we have
learned how RNA modifications – in particular in the
tRNA anticodon and the newly discovered internal
mRNA modifications – affect RNA metabolism in
unexpected ways, thus adding an unchartered layer to
translation regulation. It will be exciting to follow how
new modifications will be mapped to the transcriptome
under different conditions. However, most importantly
we will discover how those marks in trigger pheno-
types and facilitate physiological effects in different
species. An important step will be the further improve-
ment of modification mapping. Deep-sequencing-based
methods have already made invaluable contributions
to our understanding of modified nucleosides and the
integration of additional enzymes and further improve-
ments of antibody-based strategies, will provide us
with novel insights.
One of the major recent advances was the discovery
how internal mRNA modifications affect gene expres-
sion and translation. While most of the studies were
performed using single mRNA modifications, it will be
very interesting to study the cross-talk between various
of this modification marks. Furthermore, it will be
important to understand whether tRNA modifications
play a role in decoding modified mRNA nucleotides
and in particular how modified mRNA nucleotides
interact with tRNA anticodon modifications during
translation. In the light of data highlighting the impact
of tRNA wobble modifications for translation quality
through optimizing decoding, translocation and ribo-
some density, it appears worthwhile to explore the
roles of other tRNA modifications. It is now well
established that gene expression regulation and human
diseases are affected by tRNA modifications. It will be
similarly important to understand which human
pathologies are linked to mRNA modifications. The
importance of RNA modifications for translation
dynamics as well as their potential to perturb transla-
tion elongation will eventually tell us whether the two
types of modifications are indeed equal sides of the
coin or whether translation is a coin with a flipside.
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